What Monocinque Retard Treats: Main Uses and Benefits

Managing Symptoms of Stable Angina

The medication is commonly used to help with conditions presenting with recurrent symptoms related to physical discomfort. It is applied across domains where additional symptomatic support is needed, especially for conditions presenting with systemic or localized discomfort.

In clinical settings, it is applied for managing symptoms that become more disruptive during flare-ups, such as those in stable angina. It is also considered relevant for managing symptom clusters associated with chronic heart failure. The long-acting use may assist with managing symptom clusters that cause discomfort, and helps address episodes that become disruptive.

Patient Benefits and Supportive Role

This medication may assist with maintaining functional stability and contributes to easing the overall symptom load. It is relevant for easing symptoms that interfere with daily functioning, such as symptoms related to systemic imbalance like breathlessness and fatigue.

“The core role of this treatment is to help manage symptoms linked to organ-specific functional stress.”

---

Quick Fact: Relief for Chronic Discomfort

Quick Fact: Relief for Chronic Chest Discomfort and Systemic Symptoms

---

Regulatory References

1. NIH DailyMed overview of Isosorbide Mononitrate

Monocinque retard eligibility is strictly defined by regulatory guidelines and is primarily intended for adults. Its use is contraindicated in several specific populations, ensuring strict limits on who may take the medicine.

Contraindicated Populations

• Patients with known hypersensitivity to any organic nitrate drug.
• Concurrent use with Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., sildenafil) or Soluble Guanylate Cyclase (sGC) Stimulators.
• Patients experiencing acute circulatory failure, shock, or with obstructive cardiac conditions like aortic stenosis or hypertrophic cardiomyopathy.
• Patients with severe anaemia or certain rare hereditary excipient intolerances.

Age and Conditional Use

• Pediatric Population: Safety and effectiveness have not been established.
• Pregnancy and Lactation: Use is not recommended unless a physician deems it essential and benefits outweigh risks.
• Conditional Use: Requires caution for older adults due to risk of hypotension and for patients who are volume depleted or have marked hepatic or renal insufficiency.
• The medicine is not indicated for the relief of acute anginal attacks.

The interaction profile for Monocinque retard (Isosorbide Mononitrate) is primarily defined by its effects on vascular tone, as documented in official prescribing information.

Contraindicated Combinations and Mandatory Restrictions

Co-administration with Phosphodiesterase Type-5 (PDE-5) Inhibitors, such as sildenafil, tadalafil, and vardenafil, is strictly prohibited due to the high risk of life-threatening severe hypotension. The concurrent use of the soluble Guanylate Cyclase (sGC) Stimulator riociguat is also formally contraindicated in regulatory documents. These prohibitions constitute a mandatory restriction against concomitant dosing.

Pharmacodynamic and Substance Interactions

Use with antihypertensive agents, including beta-blockers and calcium channel blockers, may result in additive hypotensive effects. Similarly, other vasodilators and agents such as Neuroleptics and Tricyclic Antidepressants may potentiate blood pressure lowering. Concomitant use with alcohol is documented to have additive vasodilating effects, increasing the potential for orthostatic symptoms. Food intake may reduce the rate of absorption, but the total extent of drug exposure remains unchanged. Additionally, co-administration may increase the blood levels of Dihydroergotamine. The official labels do not detail common CYP-mediated or common transporter interactions affecting the drug's clearance.

Connection to the Overall Interaction Profile

Regulatory documents establish the drug’s interaction structure primarily through pharmacodynamic reinforcement, mandating a strict ban on combinations that severely increase the risk of hypotension, while also documenting interactions with agents that pose an additive hypotensive risk.

Monocinque retard, containing isosorbide mononitrate, functions as a nitric oxide (NO) donor. Following absorption, the organic nitrate undergoes biotransformation within smooth muscle cells, liberating nitric oxide. The released NO acts as a signaling molecule, diffusing to and stimulating the enzyme soluble guanylate cyclase (sGC)

. This enzymatic action converts guanosine triphosphate (GTP) into the secondary messenger cyclic guanosine monophosphate (cGMP). The increase in intracellular cGMP initiates a molecular cascade that leads to the activation of cGMP-dependent protein kinase (PKG). PKG promotes the dephosphorylation of the myosin light chain (MLC), resulting in the relaxation of vascular smooth muscle cells. This relaxation causes widespread systemic vasodilation. Systemic vasodilation reduces both venous return to the heart (pre-load) and the resistance against which the heart pumps (after-load). The system-level physiological consequence of reduced pre-load and after-load is a reduction in myocardial oxygen demand.

How to Use Monocinque Retard: Official Administration Guidelines

Monocinque retard is an oral medication provided as an extended-release tablet. Its usage is governed by a strict time-dependent schedule that is critical for maintaining its effectiveness over long-term therapy.

---

Dosing and Frequency

The standard protocol requires the tablet to be taken once daily. Official guidelines indicate that dosing should be initiated at 30 mg or 60 mg and may be adjusted to a typical maintenance dose that ranges up to 120 mg. The exact dose is determined by a healthcare professional based on the required pattern. To ensure procedural consistency, the tablet must be consumed upon arising in the morning.

This specific timing is a mandatory component of the administration protocol, deliberately structuring a nitrate-free interval (a time without the medication, typically 7 to 14 hours) to prevent the development of tolerance during continuous use.

---

Administration Requirements

The physical handling of the medicine is crucial to its function. The extended-release tablet must be swallowed whole with fluid and should not be crushed, chewed, or divided, as this would compromise the sustained-release mechanism of the formulation. The tablet can be taken irrespective of food intake (with or without food).

If a dose is missed, professional guidance advises against taking an extra dose; the patient should simply skip the missed dose and take the next scheduled dose at the usual time the following morning.

---

Use in Specific Populations

Prescribing information generally indicates that dose adjustment is not routinely mandated for older adults or for patients with renal or hepatic impairment.

Research Evidence / Overview of Studies for Monocinque Retard

Evidence for the Prevention of Angina Pectoris

Research explored Monocinque Retard in studies involving patients diagnosed with chronic stable angina pectoris, a condition characterized by fluctuating or episodic manifestations of chest discomfort. Researchers primarily conducted short-term Randomized Controlled Trials (RCTs) and crossover studies, comparing this extended-release formulation to a placebo or other forms of nitrate treatment. These studies examined outcomes related to systemic or functional imbalance, such as how long patients could exercise before symptoms appeared (exercise tolerance), and monitored the weekly frequency of anginal attacks.

The findings describe patterns observed in the studies regarding the participants' performance during exercise tests, reporting that in observed populations, there was an association with changes in exercise duration compared to the placebo groups. The research also reports on the general safety patterns and types of events monitored during the trials. These studies help show what has been observed so far in specific patient groups.

Long-Term Studies and Follow-Up Data

Most of the key research for Monocinque Retard was conducted during defined time intervals and focused on gathering information about short-term or intermediate-term changes, typically lasting a few months. Follow-up durations were limited in these pivotal trials. There is limited information for long-term outcomes regarding the use of this drug, such as data spanning several years. Therefore, long-term effects are not fully established, and existing studies provide limited insight into the durability of the observed responses over many years of use.

Evidence in Special Populations

Monocinque Retard was observed in studies that included older adult populations with chronic stable angina. The research examined patterns observed in these older adult populations and how they differed from patterns observed in other adult study groups. However, data for certain groups remain insufficient. For instance, there is limited information available from dedicated research exploring the drug in children or adolescents, pregnant or breastfeeding individuals, or patients with severe specific high-risk comorbidities. The results apply only to the populations studied.

Key Studies & References

1. Isosorbide Mononitrate Extended-Release Tablets, USP Rx only - DailyMed (FDA Labeling)
2. Stable angina: management - NICE Guideline [CG126]

Common questions about Monocinque retard (FAQ)

Q: Is Monocinque retard a type of blood thinner?

No, Monocinque retard is not categorized as a blood thinner (anticoagulant or antiplatelet medicine) in official documents. It is classified as an Organic Nitrate and an Anti-Anginal Agent. Its primary mechanism of action is vasodilation, which means it works by widening the blood vessels.

Q: How long does Monocinque retard typically take to start working?

Monocinque retard is an extended-release formulation, designed to provide a sustained and steady concentration of the medicine over time. Because of this gradual release, it is intended for long-term preventative management and is not indicated for acute relief of sudden issues.

Q: What is the difference between Monocinque retard and regular Monocinque?

The 'retard' designation indicates that the tablet is an extended-release or sustained-release dosage form. This means the active ingredient is released slowly and carefully over time. This formulation is used to provide a longer duration of action compared to a standard, immediate-release version.

Q: Is Monocinque retard suitable for people with a history of very low blood pressure?

Regulatory documents advise caution when the medicine is used in people with a predisposition to low blood pressure (hypotension) or volume depletion. The medicine is also contraindicated (not recommended or prohibited) for use in conditions involving acute circulatory failure or shock, such as cardiogenic shock.

Q: Is Monocinque retard a cure for the condition it treats?

The medicine is indicated for the preventative and long-term management of chronic stable angina pectoris. Official regulatory information does not describe the drug as providing a cure for the underlying condition, but rather as a means of support.

Q: What is the typical long-term use expectation for Monocinque retard?

The drug is indicated for the prophylactic (preventative) management of a chronic condition, meaning treatment is intended to be long-term. However, official regulatory research summaries indicate that limited data is available for outcomes spanning several years.

Q: Can I stop taking Monocinque retard if I feel better?

Official guidance dictates that the treatment of angina should generally be a long-term, continuous process. Decisions about starting or stopping the medicine are clinical matters that should be reviewed by the prescribing healthcare provider.

Q: Are there any dietary restrictions associated with Monocinque retard?

Official information states the tablets can be taken with or without food. There are no specific dietary restrictions mandated in regulatory documents, although an interaction with alcohol is noted to increase the risk of hypotensive effects.

Q: Is Monocinque retard used to treat high blood pressure?

The medicine’s therapeutic indication is the management of chronic stable angina pectoris. While it causes vasodilation and may result in reduced blood pressure, it is not formally indicated for the treatment of primary hypertension (high blood pressure) according to regulatory documents.

Q: Why do people sometimes mention Monocinque retard and Viagra in the same discussion?

People discuss them together because regulatory labels strictly prohibit co-administration with Phosphodiesterase Type-5 (PDE-5) Inhibitors (such as sildenafil, often sold as Viagra). This restriction is mandatory due to the risk of life-threatening severe hypotension (dangerously low blood pressure).

Q: Does Monocinque retard have a withdrawal effect if stopped suddenly?

The required continuity of long-term therapy and need for medical supervision over the dosage pattern implies that abrupt cessation is not the intended use. Regulatory documents advise against sudden changes to the prescribed dosing pattern.

Q: What is the risk of overdose with Monocinque retard, as described in official documents?

Official documents detail the known symptoms of overdose, which typically include severe hypotension (very low blood pressure), a marked increase in heart rate (reflex tachycardia), and headache. Regulatory information also advises on the management (treatment) for an overdose.

Q: Where can I find the official prescribing information for Monocinque retard?

The official document is the Prescribing Information (PI) or the Summary of Product Characteristics (SmPC). These documents are available on the respective government drug agency websites that regulate the medicine (e.g., FDA, EMA, or DailyMed).

Q: Does Monocinque retard treat the cause of the condition or just the symptoms?

The drug’s mechanism is to reduce the myocardial oxygen demand by causing vasodilation, which supports heart function and helps prevent symptoms. The drug is described as a prophylactic agent, focusing on managing the condition rather than reversing its underlying pathology (cause).

Q: What does the term 'tolerance' mean when discussing Monocinque retard?

Tolerance, sometimes called tachyphylaxis, refers to a decrease in the medicine's effect following repeated or continuous administration. Official dosing instructions are specifically designed to include a nitrate-free interval to help prevent the development of this effect.

Q: How does Monocinque retard impact exercise or physical activity?

Research studies that examined the drug's effect in patients with chronic stable angina primarily monitored the drug's influence on exercise tolerance. Regulatory documents do not detail the overall impact on general daily physical activity.

Official Storage and Disposal Requirements

Storage and disposal instructions for Monocinque retard (Isosorbide Mononitrate extended-release) are established by official regulatory agencies like the FDA and are designed to maintain the medication’s stability and ensure safety.

Requirement Type	Specific Instruction
Temperature	Store at controlled room temperature (e.g., 15 C to 30 C).
Environmental Control	Protect from excess heat and moisture. Do not store in the bathroom.
Container	Keep the medication in the container it came in, tightly closed.
Child Safety	Keep out of reach of children.
Disposal	Do not flush unused medication. Dispose of according to local guidelines, such as through a drug take-back program or by mixing with an undesirable substance (e.g., used coffee grounds) and sealing in a bag before placing in household trash.